Business Segments · NOI

OM&R — NOI

Ventas OM&R — NOI increased by 0.5% to $150.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.1%, from $146.04M to $150.60M. Over 3 years (FY 2021 to FY 2025), OM&R — NOI shows relatively stable performance with a 2.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2021
Last reportedQ1 2026

How to read this metric

An increase indicates improved property-level profitability or higher occupancy, while a decrease suggests rising operating costs or declining rental income.

Detailed definition

Net Operating Income (NOI) generated specifically by the Outpatient Medical and Research (OM&R) real estate portfolio. T...

Peer comparison

Standardized across REITs as 'Property NOI' for specific asset classes like Medical Office Buildings (MOBs).

Metric ID: vtr_segment_om_r_noi

Historical Data

18 periods
 Q2 '21Q3 '21Q4 '21Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$135.97M$135.97M$135.97M$136.58M$135.32M$136.72M$144.20M$148.07M$147.95M$145.57M$146.27M$144.10M$143.33M$146.04M$146.49M$147.75M$149.90M$150.60M
QoQ Change+0.0%+0.0%+0.5%-0.9%+1.0%+5.5%+2.7%-0.1%-1.6%+0.5%-1.5%-0.5%+1.9%+0.3%+0.9%+1.5%+0.5%
YoY Change+0.5%-0.5%+5.6%+9.4%+6.5%+1.4%-2.7%-3.1%+0.3%+0.1%+2.5%+4.6%+3.1%
Range$135.32M$150.60M
CAGR+2.4%
Avg YoY Growth+2.1%
Median YoY Growth+1.4%
Current Streak5 quarters growth

Frequently Asked Questions

What is Ventas's om&r — noi?
Ventas (VTR) reported om&r — noi of $150.60M in Q1 2026.
How has Ventas's om&r — noi changed year-over-year?
Ventas's om&r — noi increased by 3.1% year-over-year, from $146.04M to $150.60M.
What is the long-term trend for Ventas's om&r — noi?
Over 3 years (2021 to 2025), Ventas's om&r — noi has grown at a 2.8% compound annual growth rate (CAGR), from $543.88M to $590.17M.
What does om&r — noi mean?
The core operating profit generated by the company's outpatient medical and research properties.